Journal: BMC Biotechnology

Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer

doi: 10.1186/s12896-025-01033-w

Figure Lengend Snippet: Interaction analysis of the control drug Gemcitabine and the proposed nutraceutical therapeutics Queuine and Thiamine with the MAP4K4 binding site. ( A ) 3D binding pose of Gemcitabine (left) and 2D representation (right) of Gemcitabine docked in the MAP4K4 binding site. ( B ) 3D and 2D binding pose of Queuine ( C ) 3D and 2D binding pose of Thiamine. Coloring schemes: hydrogen bonding (purple arrows), pi-pi stacking (green line), and pi-cation interactions (red line)

Article Snippet: The ELISA was performed following the protocol provided by the Human Mitogen-activated Protein Kinase 4 (MAP4K4) ELISA Kit, which is intended for the quantitative detection of MAP4K4 (BT Lab, Cat. no. E5689Hu) with slight modifications.

Techniques: Control, Binding Assay

Journal: BMC Biotechnology

Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer

doi: 10.1186/s12896-025-01033-w

Figure Lengend Snippet: Protein-ligand complex root mean square deviation (RMSD) ( A ) and root mean square fluctuation (RMSF) ( B ) plots for the apo, Gemcitabine, Queuine, and Thiamine bound forms of the MAP4K4 protein

Article Snippet: The ELISA was performed following the protocol provided by the Human Mitogen-activated Protein Kinase 4 (MAP4K4) ELISA Kit, which is intended for the quantitative detection of MAP4K4 (BT Lab, Cat. no. E5689Hu) with slight modifications.

Techniques:

Journal: BMC Biotechnology

Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer

doi: 10.1186/s12896-025-01033-w

Figure Lengend Snippet: Effects of different concentrations of Queuine and Gemcitabine on MAP4K4 activity. Absorbance values on the y-axis represent the enzyme amount measured using an ELISA kit, with different concentrations of Queuine ( A ) and Gemsitabine ( B ) indicated on the x-axis. The differences between the bar pairs marked with * ( p < 0.05) and *** ( p < 0.001) are significant

Article Snippet: The ELISA was performed following the protocol provided by the Human Mitogen-activated Protein Kinase 4 (MAP4K4) ELISA Kit, which is intended for the quantitative detection of MAP4K4 (BT Lab, Cat. no. E5689Hu) with slight modifications.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay

Journal: BMC Biotechnology

Article Title: In silico screening and in vitro biological evaluation reveal Queuine as a promising MAP4K4 inhibitor for treating pancreatic cancer

doi: 10.1186/s12896-025-01033-w

Figure Lengend Snippet: Synergetic effects of Queuine and Gemcitabine on MAP4K4 activity. Absorbance values represent the enzyme amount measured using an ELISA kit. The difference between bar pairs marked with *** are significant at p < 0.001

Article Snippet: The ELISA was performed following the protocol provided by the Human Mitogen-activated Protein Kinase 4 (MAP4K4) ELISA Kit, which is intended for the quantitative detection of MAP4K4 (BT Lab, Cat. no. E5689Hu) with slight modifications.

Techniques: Activity Assay, Enzyme-linked Immunosorbent Assay

Journal: Journal of Inflammation Research

Article Title: Curcumin Alleviates Osteoarthritis Through the p38MAPK Pathway: Network Pharmacological Prediction and Experimental Confirmation

doi: 10.2147/jir.s459867

Figure Lengend Snippet: Figure 5 Western blot analysis of curcumin regulation of the p38MAPK pathway. (A–C) Western blot and quantitative analysis of p38 and p-p38. (D–F) Western blot and quantitative analysis of ASK1 and MEKK3. (G and H) Western blot images and quantitative analysis of PKCδ and p-PKCδ. (I–L) Western blot and quantitative analysis of BCL-2 and caspase-3. (n = 3). *p < 0.05,** p < 0.01,***p < 0.001.

Article Snippet: Antibodies against Caspase-3, Bcl-2, PKCδ, MEKK3, ASK1, and GAPDH were purchased from Boster (Wuhan, China).

Techniques: Western Blot

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Effects of the Wenyang Zhenshuai Granule on the Expression of LncRNA-MiR143HG/miR-143 Regulating ERK5 in H9C2 Cardiomyocytes

doi: 10.1155/2021/6431007

Figure Lengend Snippet: qRT-PCR primers.

Article Snippet: Adriamycin hydrochloride was provided by Shenzhen Wanle Pharmaceutical Co., Ltd. (H44024359), SYBR Green PCR kit was purchased from Shanghai Sixin Biotechnology Co., Ltd. (BL705A), and Wenyang Zhenshuai granules were purchased from the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine Provided (201902), and ERK5 and p-ERK5 antibodies were purchased from Wuhan Boster Bioengineering Co., Ltd. (ab40908, ab5686).

Techniques: Sequencing

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Effects of the Wenyang Zhenshuai Granule on the Expression of LncRNA-MiR143HG/miR-143 Regulating ERK5 in H9C2 Cardiomyocytes

doi: 10.1155/2021/6431007

Figure Lengend Snippet: Comparison of ERK5 expression in cardiomyocytes of various groups. Note: compared with the normal control group, ∗ P < 0.05; compared with the ADR group, # P < 0.05; compared with the ADR + LncRNA-MiR143HG silence + medicated serogroup, + P < 0.05.

Article Snippet: Adriamycin hydrochloride was provided by Shenzhen Wanle Pharmaceutical Co., Ltd. (H44024359), SYBR Green PCR kit was purchased from Shanghai Sixin Biotechnology Co., Ltd. (BL705A), and Wenyang Zhenshuai granules were purchased from the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine Provided (201902), and ERK5 and p-ERK5 antibodies were purchased from Wuhan Boster Bioengineering Co., Ltd. (ab40908, ab5686).

Techniques: Comparison, Expressing, Control

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Effects of the Wenyang Zhenshuai Granule on the Expression of LncRNA-MiR143HG/miR-143 Regulating ERK5 in H9C2 Cardiomyocytes

doi: 10.1155/2021/6431007

Figure Lengend Snippet: Comparison of the expression of p-ERK5 and ERK5 proteins in cardiomyocytes of each group. (a) Normal control group, (b) LncRNA-MiR143HG overexpression group, (c) LncRNA-MiR143HG silence group, (d) ADR group, (e) ADR + medicated serum group, (f) ADR + LncRNA-MiR143HG overexpression + medicated serogroup, and (g) ADR + LncRNA-MiR143HG silence + medicated serogroup. Compared with the normal control group, ∗ P < 0.05; compared with the ADR group, # P < 0.05; compared with the ADR + LncRNA-MiR143HG silence + medicated serogroup, + P < 0.05.

Article Snippet: Adriamycin hydrochloride was provided by Shenzhen Wanle Pharmaceutical Co., Ltd. (H44024359), SYBR Green PCR kit was purchased from Shanghai Sixin Biotechnology Co., Ltd. (BL705A), and Wenyang Zhenshuai granules were purchased from the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine Provided (201902), and ERK5 and p-ERK5 antibodies were purchased from Wuhan Boster Bioengineering Co., Ltd. (ab40908, ab5686).

Techniques: Comparison, Expressing, Control, Over Expression

Journal: BMC Cancer

Article Title: MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3

doi: 10.1186/1471-2407-13-469

Figure Lengend Snippet: The expression of MAP2K3 in human HCC tissues determined by IHC

Article Snippet: The expression of MAP2K3 in clinic human HCC and matched adjacent non-tumor tissues was evaluated by immunohistochemistry staining using rabbit anti-MAP2K3 antibody (1:100, Boster, Wuhan, China).

Techniques: Expressing, Immunohistochemistry

Journal: BMC Cancer

Article Title: MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3

doi: 10.1186/1471-2407-13-469

Figure Lengend Snippet: Validation of MAP2K3 mRNA as a target of miR-21. (A) : Sequence of potential binding site of miR-21 in the 3’UTR of MAP2K3 mRNA (top panel), mutations were introduced into the binding site for generation of mutated MAP2K3 3’TUR (bottom panel). ( B and C ): Validation of miR-21 target using MAP2K3 3’UTR luciferase reporter. Cells co-transfected with pMIR-Report/MAP2K3 3’UTR (WT) or pMIR-Report/Mut-MAP2K3 3’UTR (Mut) and pAd/pri-miR-21 (B) , pAd/miR-21/inhibitor (C) , and pAd/con plasmids showed a decreased luciferase activity in pAd/pri-miR-21 cells (B) . Luciferase activity after site directed mutagenesis of the 3’UTR of MAP2K3 mRNA in the miR-21 seed sequence (pMIR-Report/Mut-MAP2K3) was significantly higher with respect to the pMIR-Report/MAP2K3 vector transfected cells ( B and C ). Results represented the mean ± SD from three independent triplicated experiments (N=9).

Article Snippet: The expression of MAP2K3 in clinic human HCC and matched adjacent non-tumor tissues was evaluated by immunohistochemistry staining using rabbit anti-MAP2K3 antibody (1:100, Boster, Wuhan, China).

Techniques: Biomarker Discovery, Sequencing, Binding Assay, Luciferase, Transfection, Activity Assay, Mutagenesis, Plasmid Preparation

Journal: BMC Cancer

Article Title: MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3

doi: 10.1186/1471-2407-13-469

Figure Lengend Snippet: miR-21 targets MAP2K3 mRNA. The HepG2 cells were infected with Ad/pri-miR-21, Ad/miR-21/inhibitor or Ad/con adenoviral vector. The expression of MAP2K3 was detected by immunoblotting analysis against anti-MAP2K3 antibody. Compared with Ad/con group, *: p <0.05. Data in A represented the mean ± SD from three independent triplicated experiments (N=9).

Article Snippet: The expression of MAP2K3 in clinic human HCC and matched adjacent non-tumor tissues was evaluated by immunohistochemistry staining using rabbit anti-MAP2K3 antibody (1:100, Boster, Wuhan, China).

Techniques: Infection, Plasmid Preparation, Expressing, Western Blot